Erion Dobi

519 total citations
31 papers, 356 citations indexed

About

Erion Dobi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Erion Dobi has authored 31 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Erion Dobi's work include Cancer Treatment and Pharmacology (10 papers), Colorectal Cancer Treatments and Studies (7 papers) and HER2/EGFR in Cancer Research (6 papers). Erion Dobi is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Colorectal Cancer Treatments and Studies (7 papers) and HER2/EGFR in Cancer Research (6 papers). Erion Dobi collaborates with scholars based in France, United States and Albania. Erion Dobi's co-authors include Xavier Pivot, L. Chaigneau, Fernando Bazán, Antoine Thiery-Vuillemin, Stéfano Kim, Cristian Villanueva, Martin Demarchi, Thierry Nguyen, L. Cals and Elsa Curtit and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Annals of Oncology.

In The Last Decade

Erion Dobi

31 papers receiving 351 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erion Dobi France 14 217 147 111 74 36 31 356
Karel Cwiertka Czechia 10 247 1.1× 123 0.8× 108 1.0× 115 1.6× 48 1.3× 45 436
Giuseppe Colantuoni Italy 13 317 1.5× 182 1.2× 86 0.8× 185 2.5× 42 1.2× 28 509
Simona Borštnar Slovenia 12 154 0.7× 78 0.5× 147 1.3× 95 1.3× 57 1.6× 42 356
Erika Matos Slovenia 8 210 1.0× 75 0.5× 199 1.8× 105 1.4× 37 1.0× 27 409
Ligang Niu China 4 220 1.0× 138 0.9× 121 1.1× 100 1.4× 31 0.9× 5 343
Carmen G. Rea Italy 7 207 1.0× 143 1.0× 69 0.6× 92 1.2× 23 0.6× 15 322
Giuseppa Ferraro Italy 10 261 1.2× 205 1.4× 101 0.9× 132 1.8× 27 0.8× 19 421
Giorgia Guaitoli Italy 12 229 1.1× 162 1.1× 121 1.1× 146 2.0× 31 0.9× 27 436
Corrado Gallo Stampino Italy 12 238 1.1× 103 0.7× 58 0.5× 183 2.5× 33 0.9× 31 419
Elsa M. Li-Ning-Tapia United States 5 129 0.6× 146 1.0× 97 0.9× 78 1.1× 23 0.6× 6 313

Countries citing papers authored by Erion Dobi

Since Specialization
Citations

This map shows the geographic impact of Erion Dobi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erion Dobi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erion Dobi more than expected).

Fields of papers citing papers by Erion Dobi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erion Dobi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erion Dobi. The network helps show where Erion Dobi may publish in the future.

Co-authorship network of co-authors of Erion Dobi

This figure shows the co-authorship network connecting the top 25 collaborators of Erion Dobi. A scholar is included among the top collaborators of Erion Dobi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erion Dobi. Erion Dobi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Spehner, Laurie, Fabrice André, Elsa Curtit, et al.. (2025). Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption. Breast Cancer Research. 27(1). 19–19. 2 indexed citations
2.
3.
Bouhaddi, Malika, Pauline Roux, Bruno Degano, et al.. (2022). Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab. Frontiers in Cardiovascular Medicine. 9. 1000846–1000846. 16 indexed citations
4.
Selmani, Zohair, Fernando Bazán, L. Chaigneau, et al.. (2022). Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry. Scientific Reports. 12(1). 3617–3617. 4 indexed citations
5.
Bazán, Fernando, Erion Dobi, Bernard Royer, et al.. (2019). Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer. BMC Cancer. 19(1). 1029–1029. 14 indexed citations
6.
Villanueva, Cristian, Antoine Thiery-Vuillemin, Luigi Mansi, et al.. (2017). Real-life study of BRCA genetic screening in metastatic breast cancer. Annals of Oncology. 28. v94–v94. 3 indexed citations
7.
Jary, Marine, Déwi Vernerey, Thierry Lecomte, et al.. (2015). Prognostic Value of Angiopoietin-2 for Death Risk Stratification in Patients with Metastatic Colorectal Carcinoma. Cancer Epidemiology Biomarkers & Prevention. 24(3). 603–612. 16 indexed citations
8.
Pivot, Xavier, Laura Mansi, L. Chaigneau, et al.. (2015). In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?. The Oncologist. 20(4). 344–350. 19 indexed citations
9.
Dobi, Erion, Astrid Pozet, Hamadi Almotlak, et al.. (2015). Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study. Molecular and Clinical Oncology. 3(6). 1208–1212. 13 indexed citations
10.
Curtit, Elsa, Erion Dobi, Laura Mansi, et al.. (2015). Efficacité, tolérance et coût de l’éribuline chez des patientes présentant un cancer du sein métastatique. Bulletin du Cancer. 102(9). 737–748. 2 indexed citations
11.
Nerich, Virginie, Elsa Curtit, Fernando Bazán, et al.. (2014). Évaluation économique de l’utilisation en routine du test Oncotype DX® dans la prise en charge des cancers du sein en Franche-Comté. Bulletin du Cancer. 101(7-8). 681–689. 6 indexed citations
12.
Fiteni, Frédéric, Marine Jary, Franck Monnien, et al.. (2014). Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy. BMC Gastroenterology. 14(1). 143–143. 19 indexed citations
13.
Romieu, Gilles, J Salvat, L. Chaigneau, et al.. (2013). Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer—Study BES 06. Targeted Oncology. 8(2). 137–143. 9 indexed citations
14.
15.
Fiteni, Frédéric, Cristian Villanueva, Fernando Bazán, et al.. (2013). Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: Impact of institutions. The Breast. 23(2). 165–169. 9 indexed citations
16.
Curtit, Elsa, Laura Mansi, É. Viel, et al.. (2012). KIT et KIT : de la biologie à la clinique. Bulletin du Cancer. 99(2). 191–197. 1 indexed citations
17.
Dobi, Erion, Franck Monnien, Stéfano Kim, et al.. (2012). Impact of STAT3 Phosphorylation on the Clinical Effectiveness of Anti-EGFR–Based Therapy in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 12(1). 28–36. 34 indexed citations
18.
Dobi, Erion, Fernando Bazán, Armelle Dufresne, et al.. (2012). Is extracapsular tumour spread a prognostic factor in patients with early breast cancer?. International Journal of Clinical Oncology. 18(4). 607–613. 14 indexed citations
19.
Villanueva, Cristian, Fernando Bazán, Stéfano Kim, et al.. (2011). Cabazitaxel. Drugs. 71(10). 1251–1258. 41 indexed citations
20.
Thiery-Vuillemin, Antoine, Erion Dobi, Thierry Nguyen, et al.. (2010). Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors. Anti-Cancer Drugs. 21(10). 958–962. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karel Cwiertka Breakdown of academic impact, for papers by Giuseppe Colantuoni Breakdown of academic impact, for papers by Simona Borštnar Breakdown of academic impact, for papers by Erika Matos Breakdown of academic impact, for papers by Ligang Niu Breakdown of academic impact, for papers by Carmen G. Rea Breakdown of academic impact, for papers by Giuseppa Ferraro Breakdown of academic impact, for papers by Giorgia Guaitoli Breakdown of academic impact, for papers by Corrado Gallo Stampino Breakdown of academic impact, for papers by Elsa M. Li-Ning-Tapia
Rankless by CCL
2026